BP
TEVA icon

BNP Paribas’s Teva Pharmaceuticals TEVA Stock Holding History

BNP Paribas’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,461
Closed -$255K – 363
2026
Q1 		$255K Hold
8,461
– – 0.01% 214
2025
Q4 		$264K Hold
8,461
– – 0.01% 229
2025
Q3 		$171K Hold
8,461
– – 0.01% 220
2025
Q2 		$142K Sell
8,461
-1,025
-11% -$16.5K ﹤0.01% 238
2025
Q1 		$146K Sell
9,486
-3,169
-25% -$56.6K 0.01% 240
2024
Q4 		$279K Buy
12,655
+4,737
+60% +$86.2K ﹤0.01% 244
2024
Q3 		$143K Buy
7,918
+7,218
+1,031% +$126K 0.01% 243
2024
Q2 		$11.4K Sell
700
-969
-58% -$14.9K ﹤0.01% 290
2024
Q1 		$23.5K Buy
+1,669
New +$21K ﹤0.01% 285

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

BNP Paribas's TEVA Position: Q2 2026 in Review

BNP Paribas sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 8,461 shares — an estimated $255K sold.

BNP Paribas first reported a position in TEVA in Q1 2024 and held it in 9 quarters. The position peaked at $279K in Q4 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • BNP Paribas reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas sold 8,461 Teva Pharmaceuticals shares in Q2 2026, an estimated $255K.
  • BNP Paribas first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • BNP Paribas's Teva Pharmaceuticals position peaked at $279K in Q4 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on BNP Paribas's 13F filing for Q2 2026, filed 13 Aug 2026.